BIO vs CLS · rev $651.0M vs P/E 44, rev $8.75B
BIO (BIO) versus Celestica Inc. (CLS) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Celestica Inc. (CLS) is a electronic components company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported CLS revenue for 2026-06-30 was $8.75B. Net income was $581.1M. CLS currently screens at market cap $17.99B and trailing P/E 43.6.
BIO currently screens at market cap $0. CLS currently screens at market cap $17.99B and trailing P/E 43.6.
Not investment advice. Open the BIO and CLS stock pages for the full models.
Not investment advice.